[go: up one dir, main page]

KR930702029A - Homozygous Immunoglobulins - Google Patents

Homozygous Immunoglobulins

Info

Publication number
KR930702029A
KR930702029A KR1019930700605A KR930700605A KR930702029A KR 930702029 A KR930702029 A KR 930702029A KR 1019930700605 A KR1019930700605 A KR 1019930700605A KR 930700605 A KR930700605 A KR 930700605A KR 930702029 A KR930702029 A KR 930702029A
Authority
KR
South Korea
Prior art keywords
antibody
pharmaceutical composition
homozygous
antigen
monoclonal antibody
Prior art date
Application number
KR1019930700605A
Other languages
Korean (ko)
Inventor
에디쓰 앤 울프
하워드 브이 래프
Original Assignee
스티븐 체스노프
브리스톨-마이어즈 스퀴브 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 체스노프, 브리스톨-마이어즈 스퀴브 캄파니 filed Critical 스티븐 체스노프
Publication of KR930702029A publication Critical patent/KR930702029A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

항원에 대한 높은 결합 활성을 갖는 동종접합된 항체는 치료 활성을 증가시키고, 제약 및 진단 조성물에 이용된다. 동일한 항원 결정 인자에 결합하는 IgG군 단일 클론 항체로부터 통상적으로 제조된 동종접합체는 합성 가교에 의해 공유적으로 결합된다. 동종접합체는 선택된 항원에 대해 4가, 6가 이상의 IgG 유사분자를 제공하기 위하여 2개 이상의 면역 글로불린 단량체로 이루어진다.Homoconjugated antibodies with high binding activity to the antigen increase the therapeutic activity and are used in pharmaceutical and diagnostic compositions. Homozygotes commonly prepared from IgG group monoclonal antibodies that bind to the same antigenic determinants are covalently linked by synthetic crosslinking. Homozygotes consist of two or more immunoglobulin monomers to provide tetravalent, hexavalent or higher IgG analog molecules for the selected antigen.

동종접합체는 태반을 통과할 수 있다. 또한 이러한 동종접합체를 사용하는 치료방법이 제공된다.Homozygotes can cross the placenta. Also provided are methods of treatment using such homozygotes.

Description

동종접합된 면역 글로불린Homozygous Immunoglobulins

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 x축은 체류시간이고 y축은 A280인, IgG동종접합 혼합물의 FPLC프로필의 크로마토그램을 나타내고, A,B및 C로 표시된 피크는 각각 삼량체, 이량체 및 단량체 분획물을 표시한다. 제2도는 B군연쇄상구균의 탄수화물 군에 결합하는 인체의 IgG단일 클론 항체인 단일 클론 항체 D3의 초기 단량체에 비교한 동종 접합체(이량체 또는 삼량체)의 EIA에 있어서 증가된 결합 활성을 나타낸 것이다. 제3도는 이. 콜리 K1의 캡슐 탄수화물에 결합하는 인체의 IgG단일 클론 항체인 단일 클론 항체 5E1－G의 초기 단량체에 비교한 동종접합체(이량체 또는 삼량체)의 증가된 결합 활성을 나타낸 것이다. 제4도는 인체의 유방 종양에 관련된 항원에 결합하는 쥐의 단일 클론 항체인 BR64의 초기 단량체의 비교한 동종접합체(이량체)의 EIA에서의 증가된 결합 활성을 나타낸 것이다.FIG. 1 shows the chromatogram of FPLCpropyl of an IgG homozygous mixture, where the x axis is the retention time and the y axis is A 280 , and the peaks labeled A, B and C represent the trimer, dimer and monomer fractions, respectively. FIG. 2 shows increased binding activity in the EIA of homologous conjugates (dimers or trimers) compared to the initial monomer of monoclonal antibody D3, a human IgG monoclonal antibody that binds to the carbohydrate group of group B streptococci. . Third is this. It shows the increased binding activity of homozygotes (dimers or trimers) compared to the initial monomer of monoclonal antibody 5E1-G, the human IgG monoclonal antibody that binds to the capsular carbohydrate of Colli K1. Figure 4 shows the increased binding activity in EIA of the comparative homozygotes (dimer) of the initial monomers of BR64, a mouse monoclonal antibody that binds to antigens associated with human breast tumors.

Claims (23)

동일한 항원 결정인자에 결합하는 2개 이상의 IgG항체 분자를 갖는 공유 가교되어 동종접합된 단일 클론항체, 및 제약학적으로 허용 가능한 담체로 이루어지는 제약 조성물.A pharmaceutical composition comprising a covalently crosslinked homozygous monoclonal antibody having two or more IgG antibody molecules that bind to the same antigenic determinant, and a pharmaceutically acceptable carrier. 제1항에 있어서, 동종접합된 단일 클론 항체가 2개의 항체 분자를 갖는 제약 조성물.The pharmaceutical composition of claim 1, wherein the homozygous monoclonal antibody has two antibody molecules. 제1항에 있어서, 동종접합된 단일 클론 항체가 3개의 항체 분자를 갖는 제약 조성물.The pharmaceutical composition of claim 1, wherein the homozygous monoclonal antibody has three antibody molecules. 제1항에 있어서, 항체가 이황화 결합에 의해 가교된 제약 조성물.The pharmaceutical composition of claim 1, wherein the antibody is crosslinked by disulfide bonds. 제1항에 있어서, 항체가 인체의 항체인 제약 조성물.The pharmaceutical composition of claim 1, wherein the antibody is an antibody of a human body. 제1항에 있어서, 항체 분자가 쥐의 항체인 제약 조성물.The pharmaceutical composition of claim 1, wherein the antibody molecule is a mouse antibody. 제1항에 있어서, 항체 분자가 쥐－인간 키메라(chimera)항체인 제약 조성물.The pharmaceutical composition of claim 1, wherein the antibody molecule is a murine-human chimera antibody. 제5항에 있어서, 인체의 항체 중쇄가 IgG1인 제약 조성물.The pharmaceutical composition of claim 5, wherein the antibody heavy chain of the human body is IgG 1 . 제1항에 있어서, 이. 콜리(E. coli) K1에 의한 감염에 대해 보호적인 제약 조성물.The method of claim 1, wherein: Pharmaceutical compositions that are protective against infection by E. coli K1. 제1항에 있어서, B군 연쇄상구균에 의한 감염에 대해 보호적인 제약 조성물.The pharmaceutical composition according to claim 1, which is protective against infection by Group B streptococci. 제1항에 있어서, 동종접합된 단일 클론 항체가 종양 관련 항원에 결합하고, 유방 종양 세포의 성장을 억제하는 제약 조성물.The pharmaceutical composition of claim 1, wherein the homozygous monoclonal antibody binds to tumor associated antigens and inhibits the growth of breast tumor cells. 제1항에 있어서, 동종접합된 단일 클론 항체가 태반을 통과할 수 있는 제약 조성물.The pharmaceutical composition of claim 1, wherein the homozygous monoclonal antibody can cross the placenta. 제1항에 있어서, 항체 분자의 경쇄 및 중쇄의 일정 영역이 인체의 것인 제약 조성물.The pharmaceutical composition of claim 1, wherein the regions of the light and heavy chains of the antibody molecule are of the human body. 제1항에 있어서, 가교된 항체가 동일한 세포주로부터 유도된 제약 조성물.The pharmaceutical composition of claim 1, wherein the crosslinked antibody is derived from the same cell line. 동일한 항원 결정 인자에 결합하는 2개 이상의 공유 가교된 IgG항체 분자를 포함하는 동종접합된 단일 클론 항체의 치료학적 유효량을 환자에게 투여하는 것으로 이루어지는, 항원에 관련된 질병을 앓고 있는 환자의 치료방법.A method of treating a patient suffering from a disease associated with an antigen, comprising administering to the patient a therapeutically effective amount of a homozygous monoclonal antibody comprising two or more covalently crosslinked IgG antibody molecules that bind to the same antigenic determinant. 제15항에 있어서, 항원 관련 질병이 B군 연쇄상구균 감염인 방법.The method of claim 15, wherein the antigen related disease is Group B streptococcal infection. 제15항에 있어서, 항원 관련 질병이 이. 콜리 K1 감염인 방법.The method of claim 15, wherein the antigen related disease is E. coli. How is Collie K1 infection. 제15항에 있어서, 동종접합된 단일 클론 항체를 임산부 환자에게 투여하고, 동종접합체가 태반을 통해 태아의 순환계로 통과할 수 있는 방법.The method of claim 15, wherein the homozygous monoclonal antibody is administered to the pregnant patient and the homozygous can pass through the placenta into the fetal circulation. 제18항에 있어서, 동종접합된 단일 클론 항체가 태아의 항원 관련 질병을 치료할 수 있는 방법.The method of claim 18, wherein the homozygous monoclonal antibody can treat an antigen related disease of the fetus. 제19항에 있어서, 항원 관련 질병이 B군 연쇄상구균 또는 이. 콜리 K1에 의한 감염인 방법.The method of claim 19, wherein the antigen-associated disease is Group B streptococci or E. coli. The method is infection with Colli K1. 제15항에 있어서, 항원 관련 질병이 유방 종양이고, 동종접합된 단일 클론 항체가 유방종양 관련 항원에 결합하는 방법.The method of claim 15, wherein the antigen-associated disease is a breast tumor and the homozygous monoclonal antibody binds to a breast tumor-associated antigen. 항원 관련 질병의 치료를 위해 단일 클론 항체를 치료적 투여하는 방법에 있어서, 항원의 동일한 항원결정 인자에 결합하는 2개 이상의 공유 가교된 IgG항체 분자를 포함하는 동종접합된 단일 항체를 환자에게 투여하는 것으로 이루어지는 개선된 방법.A method of therapeutically administering a monoclonal antibody for the treatment of an antigen related disease, comprising administering to a patient a homozygous single antibody comprising two or more covalently crosslinked IgG antibody molecules that bind to the same antigenic determinant of the antigen. Improved method. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930700605A 1990-08-31 1991-08-29 Homozygous Immunoglobulins KR930702029A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57572590A 1990-08-31 1990-08-31
US575,725 1990-08-31
US74866291A 1991-08-26 1991-08-26
US748,662 1991-08-26
PCT/US1991/006195 WO1992004053A1 (en) 1990-08-31 1991-08-29 Homoconjugated immunoglobulins

Publications (1)

Publication Number Publication Date
KR930702029A true KR930702029A (en) 1993-09-08

Family

ID=27076774

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930700605A KR930702029A (en) 1990-08-31 1991-08-29 Homozygous Immunoglobulins

Country Status (11)

Country Link
EP (1) EP0547137A4 (en)
JP (1) JPH06500780A (en)
KR (1) KR930702029A (en)
AU (1) AU8506991A (en)
CA (1) CA2090317A1 (en)
FI (1) FI930846L (en)
IE (1) IE913071A1 (en)
IL (1) IL99363A0 (en)
NZ (1) NZ239617A (en)
PT (1) PT98840A (en)
WO (1) WO1992004053A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2281300A (en) * 1993-08-26 1995-03-01 Merck & Co Inc Anti-HIV antibody oligomer
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
AU2005227326B2 (en) 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP2325207B1 (en) 2004-11-12 2017-03-15 Xencor, Inc. FC variants with altered binding to FCRN
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1931709B1 (en) 2005-10-03 2016-12-07 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US7973136B2 (en) 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
SI2383297T1 (en) 2006-08-14 2013-06-28 Xencor Inc. Optimized antibodies that target CD19
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
EP2235059B1 (en) 2007-12-26 2015-02-18 Xencor, Inc. Fc variants with altered binding to fcrn
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
MX2011010166A (en) 2009-04-07 2011-10-11 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies.
CN102361883A (en) 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 Bispecific anti-erbb-1/anti-c-met antibodies
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
AR080794A1 (en) 2010-03-26 2012-05-09 Hoffmann La Roche BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2
AR080793A1 (en) 2010-03-26 2012-05-09 Roche Glycart Ag BISPECIFIC ANTIBODIES
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CN104105711B (en) 2012-02-10 2018-11-30 弗·哈夫曼-拉罗切有限公司 Single-chain antibody and other heteromultimerics
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
BR112014028368A2 (en) 2012-06-27 2017-11-14 Hoffmann La Roche method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation
EP2867253B1 (en) 2012-06-27 2016-09-14 F. Hoffmann-La Roche AG Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
WO2014006123A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Anti-biotin antibodies and methods of use
KR20150023938A (en) 2012-07-04 2015-03-05 에프. 호프만-라 로슈 아게 Anti-theophylline antibodies and methods of use
CN104428006B (en) 2012-07-04 2017-09-08 弗·哈夫曼-拉罗切有限公司 The antigen-antibody conjugate of covalent attachment
CN104341504B (en) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 Bispecific antibody
CA2932958A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
CN111228509A (en) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
RU2694981C2 (en) 2014-01-03 2019-07-18 Ф. Хоффманн-Ля Рош Аг Covalently linked conjugates chelicar-antibody against chelicar and use thereof
KR102278429B1 (en) 2014-01-03 2021-07-16 에프. 호프만-라 로슈 아게 Covalently linked polypeptide toxin-antibody conjugates
AR100978A1 (en) 2014-06-26 2016-11-16 Hoffmann La Roche ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME
JP6721590B2 (en) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Multispecific antibody
ES2809728T3 (en) 2015-06-24 2021-03-05 Hoffmann La Roche Humanized anti-tau (pS422) antibodies and procedures for use
WO2017214151A1 (en) 2016-06-06 2017-12-14 Northwestern University Fusion protein construct
KR20200085820A (en) * 2017-11-07 2020-07-15 휴비트 제노믹스 가부시키가이샤 How to prevent the acquisition of allergic predisposition in infants through the inhibitory effect of immune responses specific to the IgE class

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422653D0 (en) * 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
JPH04505709A (en) * 1989-11-07 1992-10-08 ブリストル―マイアーズ　スクイブ　カンパニー oligomeric immunoglobulin

Also Published As

Publication number Publication date
EP0547137A4 (en) 1993-12-08
CA2090317A1 (en) 1992-03-01
NZ239617A (en) 1993-11-25
JPH06500780A (en) 1994-01-27
EP0547137A1 (en) 1993-06-23
PT98840A (en) 1992-07-31
IE913071A1 (en) 1992-03-11
FI930846A0 (en) 1993-02-25
IL99363A0 (en) 1992-08-18
FI930846L (en) 1993-04-05
WO1992004053A1 (en) 1992-03-19
AU8506991A (en) 1992-03-30

Similar Documents

Publication Publication Date Title
KR930702029A (en) Homozygous Immunoglobulins
Boulianne et al. Production of functional chimaeric mouse/human antibody
US5055289A (en) Interferon antibody therapeutic compositions having an extended serum half-life
Dalakas et al. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy
US4844893A (en) EX vivo effector cell activation for target cell killing
Shen et al. Heteroantibody-mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG.
US6197298B1 (en) Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
JPH07246091A (en) Method for selective production of hybridoma cell strain for producing monoclonal antibody having high cytotoxicity against human cd16-antigen and method for production of cd30-hrs-3-antibody for treating double specific monoclonal antibody and human tumor using said monoclonal antibody
BR112020014380A2 (en) ANTI-MESOTELLIN ANTIBODY AND ANTIBODY DRUG CONJUGATE OF THE SAME
JPH10502544A (en) Anti-CD30 antibody that prevents proteolytic cleavage and release of membrane-bound CD30 antigen
DE69033181T2 (en) IGA RECEPTOR-SPECIFIC MONOCLONAL ANTIBODIES
KR927003816A (en) Antibody to CD3
PT712307E (en) METHODS FOR CONTROL OF THE POPULATION OF CELLS B
KR900013986A (en) Monoclonal Antibodies to Tumor-Related Antigens (MAb_s), Methods for Making and Uses thereof
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
US5830473A (en) Antibodies against T cells as therapeutics
Loop et al. Two human tumor‐associated antigens, p155 and p210, detected by monoclonal antibodies
Abbas et al. Antigen‐antibody complexes suppress antibody production by mouse plasmacytoma cells in vitro
RU2127122C1 (en) Composition showing cytotoxic effect, a method of treatment of leukemic cell in vitro
Masat et al. A simpler sort of antibody.
Lundgren et al. Cytotoxicity of human lymphocytes: antagonism between inducing processes
EP0569141A2 (en) Methods of inhibiting the growth of multidrug resistant tumors with an antibody
Moroz et al. Surface immunoglobulin of mouse thymus cells and its in vitro biosynthesis
CA2074662A1 (en) Anti-idiotypic antibodies that mimic tnf
JPS6127926A (en) Cellular toxicity drug composition and selective killing method for target cell

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930227

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid